- Home
- NWGL vs BTAI Comparison
NWGL vs BTAI Comparison
Compare NWGL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWGL
- BTAI
- Stock Information
- Founded
- NWGL 2008
- BTAI 2017
- Country
- NWGL Macau
- BTAI United States
- Employees
- NWGL N/A
- BTAI N/A
- Industry
- NWGL
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- NWGL
- BTAI Health Care
- Exchange
- NWGL Nasdaq
- BTAI Nasdaq
- Market Cap
- NWGL 19.9M
- BTAI 18.1M
- IPO Year
- NWGL 2023
- BTAI 2018
- Fundamental
- Price
- NWGL $1.30
- BTAI $0.34
- Analyst Decision
- NWGL
- BTAI Buy
- Analyst Count
- NWGL 0
- BTAI 4
- Target Price
- NWGL N/A
- BTAI $2.81
- AVG Volume (30 Days)
- NWGL 8.5K
- BTAI 1.3M
- Earning Date
- NWGL 11-29-2024
- BTAI 03-11-2025
- Dividend Yield
- NWGL N/A
- BTAI N/A
- EPS Growth
- NWGL N/A
- BTAI N/A
- EPS
- NWGL N/A
- BTAI N/A
- Revenue
- NWGL $21,707,613.00
- BTAI $2,276,000.00
- Revenue This Year
- NWGL N/A
- BTAI $131.23
- Revenue Next Year
- NWGL N/A
- BTAI $45.79
- P/E Ratio
- NWGL N/A
- BTAI N/A
- Revenue Growth
- NWGL N/A
- BTAI 83.25
- 52 Week Low
- NWGL $1.04
- BTAI $0.30
- 52 Week High
- NWGL $21.97
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- NWGL 54.56
- BTAI 42.14
- Support Level
- NWGL $1.09
- BTAI $0.33
- Resistance Level
- NWGL $1.35
- BTAI $0.39
- Average True Range (ATR)
- NWGL 0.08
- BTAI 0.06
- MACD
- NWGL 0.02
- BTAI -0.00
- Stochastic Oscillator
- NWGL 82.26
- BTAI 9.27
About NWGL Nature Wood Group Limited
Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers. Geographically, the company generates a majority of its revenue from China.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.